

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Confirmation Number	8060
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ²	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1.	5-070346	JP	A	1993-03-23	KUREHA CHEMICAL IND CO LTD		Abstract

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1.	H. ADLERCREUTZ, et al., "Determination of Urinary Lignans and Phytoestrogen Metabolites, Potential Antiestrogens and Anticarcinogens, in Urine of Women on Various Habitual Diets", Proceedings of the XII International Study Group for Steroid Hormones, (Rome, 2-4 December 1985), pages 791-797	
	2.	BEVERLY A. TEICHER, et al., "Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma", Cancer Chemother Pharmacol (1996) 38: 169-177	
	3.	SARA CALTAGIRONE, et al., "Flavonoids Apigenin and Quercetin Inhibit Melanoma Growth and Metastatic Potential", Int. J. Cancer: 87, (2000), pages 595-600	
	4.	HILARY J. CROSS, et al., "Effect of Quercetin on the Genotoxic Potential of Cisplatin", Int. J. Cancer: 66 (1996), pages 404-408	
	5.	JOHANN HOFMANN, et al., "Enhancement of the Antiproliferative Activity of Cis-Diamminedichloroplatinum(II) By Quercetin", Int. J. Cancer: 45, (1990), pages 536-539	
	6.	MORAG C.E. MCFADYEN, et al., "Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance", Biochemical Pharmacology 62 (2001), pages 207-212	
	7.	YASUYUKI SADZUKA, et al., "Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance", Toxicology Letter 114, (2000) pages 155-162	
	8.	AGNIESZKA SIWINSKA, et al., "Potentiation of the Antiproliferative Effect in Vitro of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D", Anticancer Research 21: (2001), pages 1925-1930	
	9.	JUSTYNA STAWINSKA, et al., "The reactivity of cis-platin. Spectroscopic properties of products isolated from the [cis-Pt(NH ₃) ₂ Cl ₂ -quercetin] and [cis-Pt(NH ₃) ₂ Cl ₂ -C ¹⁴ -quercetin] systems," Transition Metal Chemistry 26: 2001, pages 153-159	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Confirmation Number	8060
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	10.	YUICHIRO TAKEDA, et al, "Reversal of Multidrug Resistance By Tyrosine-Kinase Inhibitors in a Non-P-Glycoprotein-Mediated Multidrug-Resistant Cell Line", Int. J. Cancer: 57, (1994), pages 229-239	
	11.	ELZBIETA ZYNER, et al, "Platinum(II) and Palladium(II) N,O-Chelates With Substituted Flavanone Containing Ligands", Drug Research, Vol. 56, No. 2, 1999, pages 159-167	
	12.	Database Medline - XP008099672 & Am J Resp Cell 1997, 17, 51-59	

EXAMINER SIGNATURE

Examiner Signature	/Benjamin Packard/	Date Considered	10/22/2010
--------------------	--------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.